MInimal Residual Disease Adapted Strategy
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
MInimal Residual Disease Adapted Strategy is a clinical trial[1].
Key Facts
- MInimal Residual Disease Adapted Strategy is in the country of France[2].
- MInimal Residual Disease Adapted Strategy's instance of is recorded as clinical trial[3].
- MInimal Residual Disease Adapted Strategy's start time is recorded as +2021-09-01T00:00:00Z[4].
- MInimal Residual Disease Adapted Strategy's end time is recorded as +2024-09-01T00:00:00Z[5].
- MInimal Residual Disease Adapted Strategy's contributor to the creative work or subject is recorded as Sanofi[6].
- MInimal Residual Disease Adapted Strategy's contributor to the creative work or subject is recorded as Bristol-Myers Squibb[7].
- MInimal Residual Disease Adapted Strategy's main subject is recorded as autograft[8].
- MInimal Residual Disease Adapted Strategy's main subject is recorded as multiple myeloma[9].
- MInimal Residual Disease Adapted Strategy's main subject is recorded as residual neoplasm[10].
- MInimal Residual Disease Adapted Strategy's number of participants is recorded as {'unit': '1', 'amount': '+716'}[11].
- MInimal Residual Disease Adapted Strategy's title is recorded as MInimal Residual Disease Adapted Strategy: Frontline Therapy for Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years; a Prospective Study[12].
- MInimal Residual Disease Adapted Strategy's short name is recorded as MIDAS[13].
- MInimal Residual Disease Adapted Strategy's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[14].
- MInimal Residual Disease Adapted Strategy's ClinicalTrials.gov ID is recorded as NCT04934475[15].
- MInimal Residual Disease Adapted Strategy's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+66'}[16].
- MInimal Residual Disease Adapted Strategy's research intervention is recorded as (RS)-lenalidomide[17].
- MInimal Residual Disease Adapted Strategy's clinical trial phase is recorded as phase III clinical trial[18].
- MInimal Residual Disease Adapted Strategy's research site is recorded as Curie Institute[19].
- MInimal Residual Disease Adapted Strategy's research site is recorded as Centre hospitalier Annecy Genevois[20].
- MInimal Residual Disease Adapted Strategy's research site is recorded as Centre Henri-Becquerel[21].
- MInimal Residual Disease Adapted Strategy's research site is recorded as Institut Gustave Roussy[22].
- MInimal Residual Disease Adapted Strategy's research subject recruitment status is recorded as not yet recruiting[23].
- MInimal Residual Disease Adapted Strategy's study type is recorded as interventional study[24].